Black Diamond Therapeutics Announces FDA Notified Co. That It May Only Enroll Up To 50 Patients In Phase 2 of BDTX-189; Co. Announces 'The Company has initiated the GLP toxicology studies and does not anticipate any delays to its clinical trial timelines'

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!